Tomas Lindahl, MD & professor

Tomas Lindahl is founder and CEO of Diapensia HB. The company started 1992, same year a patent application was filed, later approved in US, No 5776697, “Characterization or determination of the amount of blood cells by means of poultry antibodies” and in EU countries, No 593558.

Lindahl is working as professor at Linköping University, Department of Clinical and Experimental Medicine, in Linköping, Sweden and doing research about haemostasis. Lindahl has approximately 120 publications in scientific journals and has been main tutor for 7 students achieving PhD and is main tutor for 4 PhD students. Lindahl is member of board for the diagnostic companies Medirox and Nordic Haemostasis and the professional non-profit organisation Swedish Association on Thrombosis and Haemostasis.